In spite of the great success of prostacyclin receptor agonists as therapeutic agents for PAH, their pharmacological effects on the pathology of PAH, such as complex occlusive vascular remodeling and mortality risk associated with RV failure, have not yet been elucidated. The gene discussed is PTGIR; the disease is pulmonary arterial hypertension.